Back to list

CeleCor Therapeutics

Pharmaceuticals company with a recent SEC Form D offering.
Biotech 📍 DEL MAR, CALIFORNIA
Current Valuation
Private
PRIVATE

IPO Outlookprivate

Is CeleCor Therapeutics going public?
No. CeleCor Therapeutics is private and has not filed to go public. There is no S-1 on file.
What is CeleCor Therapeutics' valuation in 2026?
No confirmed valuation is on record for CeleCor Therapeutics. The roster shows funding and investors where they are public; it does not estimate a mark.
Has CeleCor Therapeutics filed an S-1?
No public S-1 is on file for CeleCor Therapeutics.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Pharmaceuticals company headquartered in DEL MAR, CALIFORNIA. Filed SEC Form D on 20260709 for a $11.9M Regulation D offering.

Company Profile

HQ
DEL MAR, CALIFORNIA
Total Raised
$11.86M
Growth
Filed SEC Form D on 20260709 for $11.9M Regulation D offering
Last Round
Form D filing — $11.86M (20260709)
IPO Status
private

Fundraising Status

Form D filing · $11.86M
privateTotal raised $11.86M

Latest Funding Round

RoundAmountDateLead InvestorPost-Money
Form D filing$11.86M20260709

Vertical Intelligence — Biotech / Gene Therapy

Registered trials
3
1 active · 0 recruiting
Lead phase
Phase 3
most advanced registered study
Focus areas
Coronary Disease
ST-elevation Myocardial Infarction (STEMI) · Myocardial Infarction
Latest trial start
2021-04-24
Name-verified against lead sponsor "CeleCor Therapeutics" on ClinicalTrials.gov as of 2026-08-20. Verify on ClinicalTrials.gov ↗

Talent Signal

No public careers page or job board could be found for CeleCor Therapeutics as of 2026-08-17. That itself is a datapoint: no open external hiring surface.
Checked the company site and major hosted job boards. Re-checked monthly.
BiotechForm DRecently Funded
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of recent date. Refreshed quarterly.